Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

A Single Mouse Trial Platform for Evaluation of Novel Agents in Acute Lymphoblastic Leukemia By the Pediatric Preclinical Testing Consortium

Richard B. Lock, PhD, Kathryn Evans, Tara Pritchard, Cara Toscan, Chelsea Mayoh, Beverly Teicher, Raushan T Kurmasheva, Peter J Houghton, Malcolm Smith, MD PhD

Blood (2018) 132 (Supplement 1): 4010.

https://doi.org/10.1182/blood-2018-99-113207

Published: 2018

Journal Articles

Topoisomerase I-DNA Covalent Complexes in Myeloid Malignancies: A Potential Biomarker for Topoisomerase I Inhibitor Sensitivity

Mira A. Kohorst, MD, Karen S. Flatten, Kevin L. Peterson, Paula A. Schneider, Cristina Correia, Keith W. Pratz, MD, B. Douglas Smith, MD, Scott H. Kaufmann, MD PhD

Blood (2018) 132 (Supplement 1): 5146.

https://doi.org/10.1182/blood-2018-99-115667

Published: 2018

Journal Articles

Irinotecan Induces Complete Remission in MLL -Rearranged Acute Lymphoblastic Leukemia Xenografts

Patricia Garrido Castro, PhD, Mark Kerstjens, MSc, Sandra S Pinhanços, MSc, Pauline Schneider, BSc, Priscilla Wander, MSc, Rob Pieters, MD PhD, Ronald Stam, PhD

Blood (2017) 130 (Supplement 1): 3877.

https://doi.org/10.1182/blood.V130.Suppl_1.3877.3877

Published: 2017

Journal Articles

Acute Leukemias Following a Diagnosis of Colorectal Cancer: Are They Therapy-Related?

Eytan M. Stein, MD, Vipul Pareek, MD, David Kudlowitz, Dan Douer, MD, Martin S Tallman, MD

Blood (2012) 120 (21): 1453.

https://doi.org/10.1182/blood.V120.21.1453.1453

Published: 2012

Journal Articles

Phase I Trial of the Oral Poly (ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888, V) Combined Wtih Topoecan (T) and Carboplatin (C) for Adults with Relapsed and Refractory Acute Leukemias,

Keith W. Pratz, MD, Scott H. Kaufmann, MD, PhD, Mark R. Litzow, MD, Jiuping Ji, PhD, Alice Chen, MD, Michelle A Rudek, Judith E. Karp, MD

Blood (2011) 118 (21): 3634.

https://doi.org/10.1182/blood.V118.21.3634.3634

Published: 2011

Journal Articles

Phase I Trial of the Oral Poly (ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888, V) Combined Wtih Topoecan (T) and Carboplatin (C) for Adults with Relapsed and Refractory Acute Leukemias

Judith E. Karp, MD, Keith W Pratz, MD, Mark R. Litzow, MD, Jiuping Ji, PhD, Alice Chen, MD, Michelle Rudek, PharmD, PhD, Scott H. Kaufmann, MD, PhD

Blood (2010) 116 (21): 3276.

https://doi.org/10.1182/blood.V116.21.3276.3276

Published: 2010

Journal Articles

Epratuzumab (Humanized Anti-CD22 MAb) Conjugated with SN-38, a New Antibody-Drug Conjugate (ADC) for the Treatment of Hematologic Tumors: Preclinical Studies Alone and In Combination with Veltuzumab, a Humanized Anti-CD20 MAb

David M Goldenberg, Sc.D., M.D., Serengulam Govindan, Ph.D., Tom M Cardillo, Ph.D., Robert M Sharkey, Ph.D.

Blood (2010) 116 (21): 3941.

https://doi.org/10.1182/blood.V116.21.3941.3941

Published: 2010

Journal Articles

Phase I/II Trial of High-Dose Melphalan (M) and Topotecan (T) Followed by Autologous Stem Cell Rescue in Patients ≤ 60 and > 60 Years of Age with Multiple Myeloma (MM).

Daniel Sullivan, MD, Melissa Alsina, MD, Claudio Anasetti, MD, Teresa Field, MD, PhD, Mohamed Kharfan-Dabaja, MD, Hugo Fernandez, MD, William Dalton, PhD, MD, Ernesto Ayala, MD, Jyoti Raychaudhuri, MD, Lia Perez, MD, Janelle Perkins, PharmD, Michael Schell, PhD, Christine McIsaac, RN, Beth Maddox, RN, Jana Gump, BS, Richard Lush, PhD, Tony Frudakis, PhD

Blood (2007) 110 (11): 943.

https://doi.org/10.1182/blood.V110.11.943.943

Published: 2007

Journal Articles

Overexpression of Carboxylesterase-2 Results in Enhanced Efficacy of Topoisomerase I Inhibitor, Irinotecan (CPT-11), for Refractory Multiple Myeloma.

Hiroki Yano, MD, Satoshi Kayukawa, M.D., Shinsuke Iida, M.D., Chiharu Nakagawa, Ph.D., Takaomi Sanda, M.D. Ph.D., Shigeru Kusumoto, M.D., Takashi Ishida, M.D. Ph.D., Hirokazu Komatsu, M.D., Atsushi Suzuki, Ph.D., Ryuzo Ueda, M.D.

Blood (2006) 108 (11): 5107.

https://doi.org/10.1182/blood.V108.11.5107.5107

Published: 2006

Journal Articles

Discovery of novel immunostimulants by dendritic-cell–based functional screening

Norikatsu Mizumoto, Jimin Gao, Hironori Matsushima, Yasushi Ogawa, Hiroaki Tanaka, Akira Takashima

Blood (2005) 106 (9): 3082–3089.

https://doi.org/10.1182/blood-2005-03-1161

Published: 2005

Journal Articles

JNK Activation and Fas Up-Regulation Precede Proteasomal Degradation of Topoisomerase I in SN38-Mediated Cytotoxicity Against Multiple Myeloma.

Laurence Catley, MBBS, FRACP, FRCPA, Yu-Tzu Tai, PhD, Reshma Shringarpure, PhD, Renate Burger, PhD, Moni Son, Klaus Podar, MD, PhD, Dharminder Chauhan, PhD, Teru Hideshima, MD, PhD, Louis Denis, MD, Paul G. Richardson, MD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD

Blood (2004) 104 (11): 3413.

https://doi.org/10.1182/blood.V104.11.3413.3413

Published: 2004

Journal Articles

Phase II Study of Timed Sequential Therapy (TST) with Topotecan, Cytosine Arabinoside (ARA-C), and Mitoxantrone (TAM) Induction Therapy Followed by Non-Cross-Resistant Consolidation Chemotherapy for Adults with Newly Diagnosed Acute Myelogenous Leukemia (AML).

Ivana Gojo, MD, Lawrence Morris, MD, Chuanfa Guo, PhD, Meyer Heyman, MD, Michael Tidwell, NP, Jackie Greer, RN, Maureen Klein, RN, Marianne Irani, PharmD, Judith Karp, MD

Blood (2004) 104 (11): 876.

https://doi.org/10.1182/blood.V104.11.876.876

Published: 2004

Journal Articles

ERRATUM

Blood (1997) 90 (11): 4663.

https://doi.org/10.1182/blood.V90.11.4663

Published: 1997

NARROW

A Single Mouse Trial Platform for Evaluation of Novel Agents in Acute Lymphoblastic Leukemia By the Pediatric Preclinical Testing Consortium

Topoisomerase I-DNA Covalent Complexes in Myeloid Malignancies: A Potential Biomarker for Topoisomerase I Inhibitor Sensitivity

Irinotecan Induces Complete Remission in MLL -Rearranged Acute Lymphoblastic Leukemia Xenografts

Acute Leukemias Following a Diagnosis of Colorectal Cancer: Are They Therapy-Related?

Phase I Trial of the Oral Poly (ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888, V) Combined Wtih Topoecan (T) and Carboplatin (C) for Adults with Relapsed and Refractory Acute Leukemias,

Phase I Trial of the Oral Poly (ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888, V) Combined Wtih Topoecan (T) and Carboplatin (C) for Adults with Relapsed and Refractory Acute Leukemias

Epratuzumab (Humanized Anti-CD22 MAb) Conjugated with SN-38, a New Antibody-Drug Conjugate (ADC) for the Treatment of Hematologic Tumors: Preclinical Studies Alone and In Combination with Veltuzumab, a Humanized Anti-CD20 MAb

Phase I/II Trial of High-Dose Melphalan (M) and Topotecan (T) Followed by Autologous Stem Cell Rescue in Patients ≤ 60 and > 60 Years of Age with Multiple Myeloma (MM).

Overexpression of Carboxylesterase-2 Results in Enhanced Efficacy of Topoisomerase I Inhibitor, Irinotecan (CPT-11), for Refractory Multiple Myeloma.

Discovery of novel immunostimulants by dendritic-cell–based functional screening

JNK Activation and Fas Up-Regulation Precede Proteasomal Degradation of Topoisomerase I in SN38-Mediated Cytotoxicity Against Multiple Myeloma.

Phase II Study of Timed Sequential Therapy (TST) with Topotecan, Cytosine Arabinoside (ARA-C), and Mitoxantrone (TAM) Induction Therapy Followed by Non-Cross-Resistant Consolidation Chemotherapy for Adults with Newly Diagnosed Acute Myelogenous Leukemia (AML).

ERRATUM

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only